Neuroleptic malignant syndrome in patient using olanzapine;Síndrome neuroléptica maligna de paciente em uso de olanzapina

Jornal Brasileiro de Psiquiatria

Volumn 57, Issue 2, 2008, Pages 145-147

  De Medeiros, Fabrício Lins ^a,c   De Andrade, Arthur Guerra ^a,b   Hiroce, Vivian Yuri ^a   De Toledo Ferraz Alves, Tânia Corrêa ^a,b  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Atypical antipsychotics; Neuroleptic malignant syndrome; Olanzapine

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BIPERIDEN; BROMOCRIPTINE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; DANTROLENE; HALOPERIDOL; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; CASE REPORT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; DRUG FATALITY; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE; HUMAN; HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; RIGIDITY;

EID: 52049107348     PISSN: 00472085     EISSN: 19820208     Source Type: Journal    
DOI: 10.1590/s0047-20852008000200012     Document Type: Article

References (10)

1. Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome-a case review. Hum Psychopharmacol Clin Exp. 2003;18:301-9.
2. Fekadua A, Bisson JI. Neuroleptic malignant syndrome: diagnostic and therapeutic dilemmas. Behav Neurol. 2005;16:9-13.
3. Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand. 2005;112:238-40.
4. Berardi D, Dell'Atti M, Amore M, De Ronchi D, Ferrari G. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol. 2002;17:99-102.
5. Seitz DP. Diagnostic uncertainty in a case of neuroleptic malignant syndrome. CJEM. 2005;7(4):266-72.
6. American Psychiatric Association (APA). Manual diagnóstico e estatístico de transtornos mentais (DSM-IV-TR). 4a ed. 1994.
7. Kontaxakis VP, Havaki-kontaxaki BJ, Christodoulou NG, Paplos KG, Christodoulou GN. Olanzapine-associated neuroleptic malignant syndrome: is there an overlap with the serotonin syndrome? Ann Gen Hosp Psychiatry. 2003;2:10.
8. Nicholson D, Chiu W. Neuroleptic malignant syndrome. Geriatrics. 2004 ;59(8):36-40.
9. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q. 2001;72(4):325-36.
10. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364-73.